The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - EUSA Pharma
Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
 
Jennifer Foster
No Relationships to Disclose
 
Jodi Ann Muscal
Consulting or Advisory Role - Bayer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Eisai (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Oncternal Therapeutics (Inst); Pfizer (Inst); Synergene (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Lilly
 
Charles G. Minard
No Relationships to Disclose
 
Xiaowei Liu
No Relationships to Disclose
 
Joel M. Reid
No Relationships to Disclose
 
Stacey L. Berg
Research Funding - Other (Inst)
 
Elizabeth Fox
Research Funding - Ignyta (Inst); Novartis (Inst)
Other Relationship - Helsinn Therapeutics
 
Brenda Weigel
Travel, Accommodations, Expenses - Genentech; Lilly/ImClone; Nektar; Roche/Genentech; Roche/Genentech